Transcode Therapeutics, Inc.
No SEC Form 4 filings for $RNAZ in the last 30 days.
See all $RNAZ insider activity →Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
Tenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
RedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.
Over the past 7 days, alphai's AI scored 1 news story mentioning RNAZ (Transcode Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RNAZ coverage spans financial news, market movers and corporate actions.
Strong pre‑market rally suggests speculative buying.
With no new disclosed catalyst, the move is likely technical or sentiment-driven rather than fundamental re-rating.
The Phase 2a advancement and ctDNA-positive patient selection are the key catalyst that can drive biotech risk-on sentiment and volatility.
The filing confirms approvals tied to preferred-stock conversions and a Standby Equity Purchase Agreement (SEPA), which can increase future dilution risk.
A defined clinical timeline can attract event-driven positioning, though the article does not report new trial outcomes.
alphai scores every news story that mentions RNAZ with an AI model for sentiment and relevance, and aggregates insider trades from Transcode Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readRedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.
2 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001829635 0001829635 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readBiotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
7 min readTransCode Therapeutics (NASDAQ: RNAZ) has filed a shelf registration (Form S-3) to allow selling stockholders to resell up to 15.96 million shares of common stock. The company will not receive any proceeds from these sales. The filing details the outstanding shares, conversion mechanics for preferred stock, and outlines various clinical and pipeline developments for its therapeutic candidates, including TTX-MC138 and Seviprotimut-L.
2 min readTransCode Therapeutics, Inc. (RNAZ) has delayed the filing of its 2025 Form 10-K, citing complex accounting requirements following several significant transactions on October 8, 2025. These include the acquisition of ABCJ, LLC, a $25 million private placement of Series B preferred stock, and the issuance of contingent value rights (CVRs). The company requires additional time to finalize valuations and accounting for various items like IPR&D, goodwill, and deferred taxes.
3 min readTransCode Therapeutics, Inc. has appointed Jack E. Stover to its Board of Directors, where he will also join the Audit and Nominating Committees. Mr. Stover brings over three decades of executive leadership experience in life sciences, including drug development, diagnostics, and capital formation. The company anticipates his expertise will be invaluable as they advance their RNA and immuno-oncology pipelines.
2 min readCK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech unit controlled by the Li Ka-shing family.
2 min read
